Combination Therapy with R848 and Low‐Dose Sorafenib Promotes Neutrophil–DC Interactions to Enhance Antigen Presentation T Cells, Resulting in Cytotoxic CD8+ T‐Cell‐Mediated Antitumor Immunity in HCC. This evidence concerns the gene CD8A and hepatocellular carcinoma.